Mölnlycke Invests $15M in MediWound to Enhance Wound Care Solutions
Mölnlycke Invests $15M in MediWound to Enhance Wound Care Solutions
Mölnlycke Health Care, a world-leading MedTech company specialising in solutions for wound care and surgical procedures, announced today an investment of US $15m in MediWound Ltd. (NASDAQ:MDWD) (MediWound) through a definitive share purchase agreement in a private investment in public equity (PIPE). MediWound, a global leader in next-generation enzymatic therapeutics focused on non-surgical wound debridement, has a vision to improve the existing standards of care and patient experiences, while reducing costs and unnecessary surgeries.
全球領先的醫療科技公司Mölnlycke Health Care今天宣佈,通過一項明確的股份購買協議,在私募公開股權投資(PIPE)中向MediWound Ltd. (納斯達克:MDWD)(mediwound)投資1500萬美元。MediWound是下一代酶治療全球領先企業,專注於非手術性創面治療的全球貨幣,旨在改善現有的護理標準和病人體驗,同時降低成本和不必要的手術。
Debridement is a standard of care step to prepare the wound bed for healing and can help in the management of infection. It involves the removal of dead or devitalised tissue from a wound.
去腐化是準備創面癒合的標準步驟,有助於管理感染。它包括從創面中去除死亡或失活組織。
譯文內容由第三人軟體翻譯。